Precision BioSciences’ Cassie Gorsuch, PhD named CSO

Precision BioSciences (DTIL) announced enhancements within the Company’s senior leadership team. Precision continues to progress its lead in vivo gene editing program, PBGENE-HBV, through Phase 1 clinical study, while preparing to advance additional in vivo programs into clinic. Cindy Atwell is appointed to Chief Development and Business Officer where she will oversee all development functions for Precision including clinical, translational, regulatory, program leadership and management in addition to business development and alliance oversight. Cindy holds an MBA from the University of California, San Diego and a Bachelor of Science in biochemistry and molecular biology from the Pennsylvania State University. Additionally, Cassie Gorsuch, PhD has been promoted to Chief Scientific Officer overseeing non-clinical development and gene therapy discovery. Dr. Gorsuch will be responsible for preclinical proof of concept and IND-enabling data to support advancement to clinical studies. Dr. Gorsuch most recently served as Precision’s Vice President of Gene Therapy Discovery. Dr. Gorsuch has been instrumental in the advancement of the PBGENE-HBV program through preclinical studies and into the clinic. Dr. Gorsuch will continue to support external engagement and education regarding ARCUS and Precision’s gene editing efforts. Dr. Gorsuch earned her PhD in biological sciences from the University of Notre Dame and a Bachelor of Science in biochemistry from Rockhurst University.